The hyperbaric oxygen therapy (HBOT) market encompasses the development, manufacturing, and sale of hyperbaric oxygen chambers, as well as the services associated with providing HBOT to patients. This therapy involves administering 100% oxygen at elevated atmospheric pressures in specialized chambers, helping to enhance oxygen delivery to tissues where circulation is compromised. Primarily used for treating a wide array of medical conditions such as diabetic foot ulcers, decompression sickness, severe anemia, and carbon monoxide poisoning, the market is driven by the increasing prevalence of chronic wounds, technological advancements in chamber designs, and expanding indications for use. The market growth is also supported by growing healthcare expenditure globally, rising awareness of the benefits of enhanced oxygen therapy, and the ongoing clinical research that continues to validate and expand the therapeutic applications of HBOT.
Read More